AlzeCure Pharma Announces $2.2 billion Licensing and Collaboration Agreement
On 1 July 2026, AlzeCure Pharma AB disclosed that it had entered into an out‑licensing and collaboration agreement with Danish biotech QuantumCell ApS covering global rights to its Alzheimer’s platform NeuroRestore and the lead small‑molecule candidate ACD856. The transaction value exceeds US$2.2 billion, excluding any royalty payments.
Share Price Reaction
Following the announcement, AlzeCure shares jumped as much as 71 % on Wednesday, touching an intraday high of 7.24 Swedish crowns – the highest level since 10 January 2022 – before easing back. The stock closed the previous trading day at 3.87 crowns, representing a gain of more than 225 % since the start of the year.
Financial Terms
AlzeCure will receive a total upfront payment of US$12 million. Of this, US$5 million will be provided as a direct equity investment in AlzeCure at a 30 % premium to the ten‑day average share price of 3.78 crowns. The agreement also provides for development and commercial milestone payments and tiered royalties ranging from single‑digit to low double‑digit percentages on future sales.
Drug Candidate Profile
ACD856 is described as a small‑molecule positive modulator of both NGF/TrkA and BDNF/TrkB signaling pathways. Pre‑clinical studies have shown the compound can enhance neuronal communication, improve learning and memory, and exhibit neuroprotective, anti‑inflammatory, disease‑modifying, and antidepressant effects.
Executive Comments
Chief Scientific Officer Johan Sandin highlighted the positive clinical results already obtained with ACD856 and the pre‑clinical data supporting its cognitive‑enhancing, neuroprotective, and antidepressant properties, calling it an innovative candidate for a wide range of indications. CEO Martin Jönsson called the out‑licensing deal a major milestone, emphasizing that the first‑in‑class Trk‑PAM drug was developed in‑house from concept to clinical phase, showcasing AlzeCure’s capabilities.
Regulatory Conditions
The transaction is subject to customary closing conditions, including approvals from Swedish and Danish authorities under foreign direct investment regulations.